图书馆主页
数据库简介
最新动态
联系我们



返回首页


 刊名字顺( Alphabetical List of Journals):

  A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL


  检 索:         高级检索

期刊名称:NPJ VACCINES

ISSN:2059-0105
出版频率:Continuous publication
出版社:NATURE PORTFOLIO, HEIDELBERGER PLATZ 3, BERLIN, Germany, 14197
  出版社网址:https://www.nature.com/
期刊网址:https://www.nature.com/npjvaccines/
影响因子:7.344
主题范畴:IMMUNOLOGY;    MEDICINE, RESEARCH & EXPERIMENTAL
变更情况:Newly Added by 2017

期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)   



About the journal

Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.

Aims & Scope

npj Vaccines is a multidisciplinary journal that is dedicated to publishing the finest and high-quality research and development on human and veterinary vaccines, including:

  • discovery and basic science
  • nonclinical development of vaccines
  • biodefense vaccine
  • AIDS vaccine
  • vaccine formulation
  • vaccine adjuvants and conjugate vaccines
  • cancer/oncology vaccines
  • clinical evaluation of vaccines
  • vaccine safety
  • regulatory science
  • conventional and non-conventional vaccines
  • live, attenuated vaccines
  • inactivated vaccines
  • subunit vaccines
  • toxoid vaccines
  • DNA vaccines
  • recombinant vector vaccines.

Each original research article will include an Editorial Summary that will summarize the key issues being addressed within the article with the goal of keeping the readership informed of advances in the field of vaccinology.

Given the public health importance of vaccines, in addition to publishing high-quality original research, npj Vaccines also publishes commentaries, News and Views (or a similar format), research highlights, editorials, and correspondence from readers, to provide state-of-the-art information for those interested in vaccines.

Article and journal metrics

Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.

The 2017 journal metrics for npj Vaccines are as follows:

2-year Impact Factor 5-year Impact Factor Immediacy index Eigenfactor® score Article Influence Score
3.143 3.143 0.457 0.00039 2.037

For a further description of these metrics and a summary of the metrics for all Nature journals, please visit our journal metrics page.  More information underlying our approach to journal metrics may be found here.

Abstracting and Indexing

npj Vaccines is listed within leading abstracting and indexing services including Scopus, PubMed Central, PubMed, Science Citation Index Expanded (SCIE), Biological Abstracts, BIOSIS Previews and Directory of Open Access Journals (DOAJ).

 


Instructions to Authors

For Authors & Referees

npj Vaccines will publish internationally-relevant open research on human and veterinary vaccines. The journal is open for submissions.

Submit

To publish in the journal, please go to the online submission system.

Guide to Authors

View our guide to authors for detailed information on editorial criteria, and how manuscripts are handled by our editors between submission and acceptance for publication.

Benefits to Authors

Articles published in npj Vaccines are open access, allowing for the widest dissemination, visibility, and impact of your research – visit the benefits to authors page to explore the reasons why you should publish with the journal.


Instructions to Authors
npjvaccines-gta.pdf

Editorial Board

About the Editors

Editor-in-Chief

Alan D. T. Barrett, PhD
Director, Sealy Center for Vaccine Development
Department of Pathology

University of Texas Medical Branch
TX, USA

 

Alan D.T. Barrett obtained his B.S., M.S. and PhD in the area of virology from the University of Warwick, followed by a post-doctoral fellowship in arbovirology at the London School of Hygiene and Tropical Medicine. He is currently Director at the Sealy Center for Vaccine Development and World Health Organization Collaborating Center for Vaccine Research, Evaluating and Training for Emerging Infectious Diseases. He is a Professor in the Departments of Pathology and Microbiology & Immunology at University of Texas, Medical Branch (UTMB). Dr. Barrett is a leading expert in the fields of vaccine development for flavivirus and bunyavirus. His lab is undertaking basic research on the development of vaccines against the flavivirus diseases. This includes West Nile, Japanese encephalitis, yellow fever and dengue. The lab also underatkes and is funded by a number of grants from the NIH. In addition, Dr. Barrett has over 160 publications in the field and is frequently called upon to Chair NIH Special Emphasis panels for biodefense and infectious disease topics.

Associate Editors

Paul A. MacAry, PhD
Director, LSI Immunology Programme & Co-Chair CREATE-HUJ Consortium
Department of Microbiology

National University of Singapore
Singapore, Singapore

Associate Professor Paul MacAry received his BSc (Hons) in Molecular Genetics from Glasgow University in 1993 and his PhD in Immunology from GKT, University of London in 1998.  He performed post-doctoral researches in the Cambridge University Institute for Medical Research (CIMR) and since 2005 has been an independent investigator in the Department of Microbiology and Immunology program at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering applications in infectious diseases. Professor MacAry was a founding member and Meetings Secretary for the Singaporean Society of Immunology (SSI) - Singapore’s first international learned society - and the founding scientist for two biotechnology companies, BSCR LTD founded in Cambridge in 2004 and Antibody Cradle LTD founded in Singapore in 2012.

Veronika von Messling, Dr. med. vet.
Director of the Veterinary Medicine
Federal Institute for Vaccines and Biomedicines 
Paul-Ehrlich-Institut
Langen, Germany

 

Prof  Dr. Veronika von Messling is Director of the Veterinary Medicine Division at the Paul-Ehrlich Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.  She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.  After postdoctoral training at Mayo Clinic in Rochester, MN, she was an Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore. Her research interest lies in characterizing the pathogenesis of respiratory viruses to develop novel prophylactic and therapeutic strategies. Dr. von Messling has been awarded various awards and prizes such as the Chercheur-boursier senior Award, FRSQ, (2011), and the Löffler-Frosch Prize, German Society of Virology (2011). She is also a member of various societies such as the European Society of Virology, Canadian Society of Microbiology and Deutsche virologische Gesellschaft.

Pei-Yong Shi, PhD
I.H. Kempner Professor of Human Genetics,
Department of Biochemistry and Molecular Biology

University of Texas Medical Branch
TX, USA

 

Along with his post at UTMB, Pei-Yong Shi serves as adjunct Professor of Emerging Infectious Diseases at the Duke-NUS Graduate Medical School in Singapore and Honorary Professor at the Wuhan Institute of Virology, Chinese Academy of Sciences. He studies flavivirus replication and develops antivirals and vaccines. He received his PhD in virology in 1996 from Georgia State University. After postdoctoral training at Yale, he joined Bristol-Myers Squibb as a Principal Scientist to develop HIV and HCV therapeutics from 1998-2000. From 2008 to 2015, he served as Executive Director to lead drug discovery at Novartis Institute for Tropical Diseases. At UTMB, his group developed the first infectious clone of the epidemic strain of West Nile virus, discovered two cap methylation activities of flavivirus NS5 protein, identified essential RNA elements for flavivirus replication, established various platforms for flavivirus vaccine and drug discovery, and pioneered therapeutics development for dengue virus.

Richard Titball, DsC, PhD
Professor of Molecular Microbiology
School of Biosciences
University of Exeter
Exeter, United Kingdom

 

Prof. Titball has worked extensively on a range of bacterial pathogens including Burkholderia pseudomallei, Francisella tularensis, Yersinia pestis, Campylobacter jejuni and Clostridium perfringens. His past work has provided new insight into the molecular architectures and mode of action of C. perfringens toxins and he led initiatives to sequence the first genomes of a range of candidate biothreat agents. Prof. Titball’s work also resulted in the development of vaccines against plague and C. perfringens toxins which have been trialled in humans and in animals, respectively.  His principal interests now lie with understanding the molecular basis of disease caused by B. pseudomallei and C. jejuni. He continues to have a strong interest in the development of vaccines against B. pseudomallei and C. perfringens toxins. This work includes understanding the role that vaccines might have in controlling chronic and persistent disease and the use of novel vaccine delivery systems.

David H. Walker, MD, PhD
Department of Pathology
University of Texas Medical Branch
TX, USA




David Walker is the Director of the Center for Biodefense and Emerging Infectious Diseases, and Professor and former Chairman of the Department of Pathology at the University of Texas Medical Branch at Galveston. He receieved his M.D. from Vanderbilt University, and then later served as a Research and Clinical Fellow at Harvard University School of Medicine. Dr. Walker’s research has elucidated mechanisms of immunity to Rickettsia and Ehrlichia, developed animal models for investigating rickettsioses and ehrlichioses, and contributed to elucidating the pathology and pathophysiology of Lassa fever, Rocky Mountain spotted fever, Mediterranean spotted fever, and human monocytotropic ehrlichiosis. Among emerging infections, he contributed to the discovery, characterization, and/or epidemiology of Anaplasma phagocytophilum (human granulocytotropic anaplasmosis), Rickettsia japonica (Japanese spotted fever), R. felis (flea-borne spotted fever), and E. chaffeensis (human monocytotropic ehrlichiosis).

Editorial Board Members

L. Garry Adams —Texas A&M College Station, Texas, USA

Sylvie Alonso — National University of Singapore, Singapore, Singapore

Carl R. Alving — Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

Peter L. Andersen — Statens Serum Institute, Copenhagen, Denmark

Bernard Arulanandam — University of Texas at San Antonio,Texas, USA

David W. C. Beasley — University of Texas Medical Branch, Texas, USA

Martin Beer — Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany

David I. Bernstein — Cincinnati Children's Hospital Medical Center, Ohio, USA

Paul L. Bigliardi, University of Minnesota, Minnesota, USA

Danny Casimiro — Aeras, Maryland, USA

Ashok K. Chopra — University of Texas Medical Branch,Texas, USA

James Crowe — Vanderbilt University, Tennessee, USA

Denise Doolan — James Cook University, Australia

J. Stephen Dumler — Uniformed Services University for the Health Sciences, Maryland, USA

Janice Endsley — University of Texas Medical Branch (UTMB),Texas, USA

Susanna Esposito — Università degli Studi di Milano, Milan, Italy

Ali I. Fattom — NanoBio Corporation, Michigan, USA

Thomas Ficht — Texas A&M University, Texas, USA

Katja Fink —Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore

Anthony R. Fooks — Animal and Plant Health Agency (APHA), Surrey, UK

Tong-Ming Fu — Merck & Co., Philadelphia, USA

Alexander Freiberg — University of Texas Medical Branch, Texas, USA

Michael Gale, Jr. — University of Washington, Washington, USA

Adolfo Garcia-Sastre — Mount Sinai School of Medicine New York, USA

Nathalie Garcon — Bioaster Technology Research Institute, Brussels, Belgium

Nisha J. Garg — University of Texas Medical Branch,Texas, USA

Sarah Gilbert — Jenner Institute, University of Oxford, Oxford, UK

Jaap Goudsmit — University of Amsterdam, Amsterdam, Netherlands

Barney S. Graham — NIH, Maryland, USA

Beth-Ann Griswold Coller— Merck Research Laboratories, New Jersey, USA

Joachim Hombach — World Health Organization, Geneva, Switzerland

Tetsuro Ikegami — University of Texas Medical Branch, Texas, USA

Ken J Ishii — Osaka University, Osaka, Japan

Nicholas Jackson —Sanofi-Pasteur, Lyon, France

Kathrin Jansen — Pfizer Vaccine Research, New York, USA

Stefan Kappe — Seattle Biomedical Research Institute, Washington, USA

David C. Kaslow — PATH, Seattle, Washington, USA

Stephen Kent — University of Melbourne, Melbourne, Australia

Janine Kimpel — Medical University of Innsbruck, Innsbruck, Australia 

Dennis M. Klinman — National Cancer Institute, NIH, Maryland, USA

Eiji Konishi — Osaka University, Osaka, Japan

Margaret Liu — Karolinska Institute, Stockholm, Sweden

Shan Lu — University of Massachusetts Medical School, Massachusetts, USA

Mary Marovich — National Institute of Allergy and Infectious Diseases, NIH, Maryland, USA

Peter Mason — Regeneron Pharmaceuticals, Tarrytown, New York, USA

Jere W. McBride — University of Texas Medical Branch,Texas, USA

Philip Minor — National Institute for Biological Standards and Control, Potters Bar, UK

Thomas P Monath — NewLink Genetics, Iowa, USA

Kathleen M. Neuzil — University of Maryland School of Medicine, Maryland, USA

Walter Orenstein — Emory University, Georgia, USA

Slobodan Paessler — University of Texas Medical Branch, Texas, USA

Guy H. Palmer — Washington State University, Washington, USA

Daniel Paris — Mahidol Oxford Research Unit, Bangkok, Thailand

Kevin Pethe — Nanyang Technological University, Singapore

Stanley Plotkin — University of Pennsylvania, Vaxconsult, Pennsylvania, USA

Maarten Postma — University of Groningen, Groningen, Netherlands

Bali Pulendran — Emory University, Atlanta, Georgia, USA

Cheng-Feng Qin — Beijing Institute of Microbiology and Epidemiology, Beijing, China

Rino Rappuoli — GSK Vaccines, Siena, Italy

Steven G. Reed — Infectious Diseases Research Institute, Washington, USA

Guus Rimmelzwaan — Erasmus Medical Centre, Rotterdam, Zuid-Holland, Netherlands

Jai Rudra — Sealy Center for Vaccine Development, University of Texas Medical Branch, Texas, USA

Richard Rupp — University of Texas Medical Branch, Texas, USA

Robert Sauerwein — Radboud University Medical Center, Nijmegen, Netherlands

Alexander Schmidt — GSK Vaccines, Brussels, Belgium

Alessandro Sette — La Jolla Institute for Allergy and Immunology, California, USA

John Shiver — Sanofi-Pasteur Vaccines, Swiftwater, Pennsylvania, USA

Mark K. Slifka — Oregon Health & Science University, Orlando, USA

Jon Smith —PaxVax, Inc., San Diego, CA, USA

Lynn Soong — University of Texas Medical Branch, Texas, USA

J. Erin Staples — Centers for Disease Control, Colorado, USA

Geraldine Taylor — Pirbright Institute, Woking, UK

Dirk Teuwen — Union Chimique Belge (UCB), Brussels, Belgium

Ralph A. Tripp —The UGA college of Veterinary Medicine, Georgia, USA

Takafumi Tsuboi — Ehime University, Ehime, Japan

Sylvia van den Hurk— University of Saskatchewan, Saskatchewan, Canada

Kirsten Vannice — World Health Organization, Geneva, Switzerland

Hengliang Wang — Beijing Institute of Biotechnology, Beijing, China

Scott C. Weaver— University of Texas Medical Branch, Texas, USA

David B. Weiner — University of Pennsylvania, Pennsylvania, USA

Fidel Zavala — John Hopkins Bloomberg School of Public Health, Maryland, USA

Qinjian Zhao — Xiamen University, Xiamen, Fujian, China



 返回页首 


邮编:430072   地址:中国武汉珞珈山   电话:027-87682740   管理员Email:
Copyright © 2005-2006 武汉大学图书馆版权所有